Incyte Corporation

Zhiyong Yu

Wenqing Yao

Liangxing Wu

Chunhong He

Xiaozhao Wang

Colin Zhang

Ding-Quan Qian

Wenyu Zhu

Song Mei

Meizhong Xu

Liang Lu

Neil Lajkiewicz

Leah C Konkol

Le Zhao

Fenglei Zhang

Jingwei Li

Matthew S McCammant

Heeoon Han

Taisheng Huang

Chao Qi

Zhenwu Li

Yingda Ye

Kaijiong Xiao

Pei Gan

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Fused pyrimidine derivatives as A2A/A2B inhibitors

The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Heterocyclic compounds as immunomodulators

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. 

Fused pyrimidine derivatives as A2A / A2B inhibitors

The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer. 

Imidazopyridines and imidazopyrazines as LSD1 inhibitors

Substituted imidazo[1,5-&#x3b1;]pyridines and imidazo[1,5-&#x3b1;]pyrazines as LSD1 inhibitors

Growing community of inventors

Wilmington, DE, United States of America

Zhiyong Yu